AACR19: umbralisib trial results give support for use as a marginal zone lymphoma drug

Early results from the UNITY-NHL Phase II clinical trial show promise for the investigational therapeutic umbralisib as a treatment for relapsed/refractory marginal zone lymphoma. The PI3K-delta inhibitor was highly active and well tolerated in patients with 55% of patients having a partial or complete response after 6 months. “Our exciting results suggest that this oral targeted therapeutic has significant activity against relapsed/refractory marginal zone lymphoma and offers hope for patients”The results from the Phase II trial were recently presented at the AACR Annual Meeting 2019 (March 29–April 3, GA, USA). “Marginal zone lymphomais an uncommon, slow-growing type of non-Hodgkin lymphoma,” explained...